# Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants

> **NCT03169881** · PHASE3 · COMPLETED · sponsor: **NICHD Neonatal Research Network** · enrollment: 650 (actual)

## Conditions studied

- Neurocognitive
- Neuroprotective
- Neonatal
- Neurodevelopmental Impairment

## Interventions

- **DRUG:** Darbepoetin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03169881
- **Lead sponsor:** NICHD Neonatal Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-20
- **Primary completion:** 2022-12-23
- **Final completion:** 2025-05-12
- **Target enrollment:** 650 (ACTUAL)
- **Last updated:** 2025-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03169881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03169881, "Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03169881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*